Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: Blockade with SB 209670

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 1, 2000, Pages 449-459

  Burrell, Kylie M ^a   Molenaar, Peter ^a,b   Dawson, Peter J ^a   Kaumann, Alberto J ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; ATRASENTAN; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR AGONIST; RO 46 8443; SARAFOTOXIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONCENTRATION RESPONSE; DRUG BINDING SITE; DRUG POTENCY; ENDOTHELIUM CELL; FEMALE; HEART ARRHYTHMIA; HEART MUSCLE CONTRACTILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INOTROPISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; ARRHYTHMIA; ATRIAL APPENDAGE; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELINS; FEMALE; HEART VENTRICLES; HUMANS; INDANS; MALE; MIDDLE AGED; MUSCLE CONTRACTION; MYOCARDIAL CONTRACTION; RECEPTORS, ENDOTHELIN; VIPER VENOMS;

EID: 0033984199     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48-58.
2. Bax WA, Aghai Z, van Tricht CLJ, Wassenaar C and Saxena PR (1994) Different endothelin receptors involved in endothelin-1-and sarafotoxin S6B-induced contractions of the human isolated coronary artery. Br J Pharmacol 113:1471-1479.
3. Bax WA, Brunivels AT, van Suylen R-J, Saxena PR and Hoyer D (1993) Endothelin receptors in the human coronary artery, ventricle and atrium. A quantitative autoradiographic analysis. Naunyn-Schmiedeberg's Arch Pharmacol 348:403-410.
4. Bax WA and Saxena PR (1994) The current endothelin receptor classification: Time for reconsideration? Trends Pharmacol Sci 15:379-386.
5. B receptor. FEBS Lett 383:37-41.
6. 1-receptor down-regulation in heart failure. Circ Res 59:297-309.
7. Brunner F and Kukovetz WR (1996) Postischemic antiarrhythmic effects of angiotensin-converting enzyme inhibitors. Role of suppression of endogenous endothelin secretion. Circ Res 94:1752-1761.
8. Burrell KM, Bootman MD, Berridge MJ and Lipp P (1999) Underlying mechanisms of ET-1 induced arrhythmias in rat atrial myocytes. J Physiol (Lond) 518:P59.
9. Clozel M, Breu V, Gray GA, Kalina B, Löffler B-M, Burri K, Cassal J-M, Hirth G, Müller M, Neidhart W and Ramuz H (1994) Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 270:228-235.
10. Davenport AP and Masaki T (1998) Endothelin receptors, in The IUPHAR Compendium of Receptor Characterization and Classification (Girdlestone D ed) pp 152-159, IUPHAR Media, London.
11. 125I]endothelin-1 in humans, pigs, and rats: Functional relevance in humans. J Cardiovasc Pharmacol 13 (Suppl 5):S166-S170.
12. Douglas SA, Beck GR Jr, Elliott JD and Ohlstein EH (1995) Pharmacological evidence for the presence of three distinct functional endothelin receptor subtypes in rabbit lateral saphenous vein. Br J Pharmacol 114:1529-1540.
13. Douglas SA, Nichols AJ, Feuerstein GZ, Elliott JD and Ohlstein EH (1998) SB 209670 inhibits the arrhythmogenic actions of endothelin-1 in the anesthetized dog. J Cardiovasc Pharmacol 31 (Suppl 1):S99-S102.
14. Eschenhagen T (1996) Role of inhibitory G proteins for the control of catecholamine-induced cardiac arrhythmias. Naunyn-Schmiedeberg's Arch Pharmacol 354:R1.
15. 2+ transients in mouse ventricular myocytes. Naunyn-Schmiedeberg's Arch Pharmacol 360:445-456.
16. Fuller JA, Adams GG and Buxton B (1989) Atrial fibrillation after coronary artery bypass grafting. J Thorac Cardiovasc Surg 97:821-825.
17. Godfraind T (1993) Evidence for heterogeneity of endothelin receptor distribution in human coronary artery. Br J Pharmacol 110:1201-1205.
18. 2-adrenoceptors in human atrial myocardium Circ Res 66:1610-1623.
19. A receptor. Life Sci 50:247-255.
20. Jiang T, Pak E, Zhang H, Kline RP and Steinberg SF (1996) Endothelin-dependent actions in cultured AT-1 cardiac myoctyes. The role of the ∈ isoform of protein kinase C. Circ Res 78:724-736.
21. Kalman JM, Munawar M, Howes LG, Louis WJ, Buxton BF, Gutteridge G and Tonkin AM (1995) Atrial fibrillation after coronary artery bypass grafting is associated with sympathetic activation. Ann Thorac Surg 60:1709-1715.
22. 2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure. Circulation 99:65-72.
23. 1D, receptors. Circulation 90:1141-1153.
24. Kaumann AJ and Molenaar P (1997) Modulation of human cardiac function through 4 β-adrenoceptor populations. Naunyn-Schmiedeberg's Arch Pharmacol 355:667-681.
25. 2-adrenoceptors mediate catecholamine-evoked arrhythmias in isolated human right atrium. Naunyn-Schmiedeberg's Arch Pharmacol 348:536-540.
26. 4 receptors in human atrium: Facilitation by chronic β-adrenoceptor blockade. Naunyn-Schmiedeberg's Arch Pharmacol 349:331-337.
27. Knothe C, Boldt J, Schindler E, Zickmann B, Konstantinov S, Dapper F and Hempelmann G (1996) Endothelin plasma levels during heart surgery: Influence on pulmonary artery pressure? Ear J Cardio-Thorac Surg 10:579-584.
28. + exchanger. Circ Res 68:269-279.
29. 1-adrenoceptors by carvedilol in ferret myocardium. Naunyn-Schmiedeberg's Arch Pharmacol 359:400-403.
30. Maguire JJ and Davenport AP (1995) ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol 115:191-197.
31. Meyer M, Lehnart S, Pieske B, Schlottauer K, Munk S, Holubarsch C, Just H and Hasenfuss G (1996) Influence of endothelin 1 on human atrial myocardium -myocardial function and subcellular pathways. Basic Res Cardiol 91:86-93.
32. Molenaar P, O'Reilly G, Sharkey A, Kuc RE, Harding DP, Plumpton C, Gresham GA and Davenport AP (1993) Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res 72:526-538.
33. 3-adrenoceptors. Br J Pharmacol 120:165-176.
34. Moravec CS, Reynolds EE, Stewart TW and Bond M (1989) Endothelin is a positive inotropic agent in human and rat heart in vitro. Biochem Biophys Res Commun 159:14-18.
35. Ohlstein EH, Beck GR Jr, Douglas SA, Nambi P, Lago MA, Gleason JG, Ruffolo RR Jr, Feuerstein G and Elliott JD (1994a) Nonpeptide endothelin receptor antagonists. II. Pharmacological characterization of SB 209670. J Pharmacol Exp Ther 271:762-768.
36. Ohlstein EH, Nambi P, Douglas SA, Edwards RM, Gellai M, Lago A, Leber JD, Cousins RD, Gao A, Frazee JS, Peishoff CE, Bean JW, Eggleston DS, Elshourbagy NA, Kumar C, Lee JA, Yue T-L, Louden C, Brooks DP, Weinstock J, Feuerstein G, Poste G, Ruffolo RR Jr, Gleason JG and Elliott JD (1994b) SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci USA 91:8052-8056.
37. A-selective receptor antagonist. J Pharmacol Exp Ther 276:473-481.
38. 1-adrenergic receptors. J Recept Signal Transduct Res 16:1-23.
39. Panek RL, Major TC, Hingorani GP, Doherty AM, Taylor DG and Rapundalo ST (1992) Endothelin and structurally related analogs distinguish between endothelin receptor subtypes. Biochem Biophys Res Commun 183:566-571.
40. Pieske B, Beyermann B, Breu V, Loffler BM, Schlotthauer K, Maier LS, Schmidt-Schweda S, Just H and Hasenfuss G (1999) Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium. Circulation 99:1802-1809.
41. Pönicke K, Vogelsang M, Heinroth M, Becker K, Zolk O, Böhm M, Zerkowski H-R and Brodde O-E (1998) Endothelin receptors in the failing and nonfailing human heart. Circulation 97:744-751.
42. Prichard BNC, Tomlinson B, Walden RJ and Bhattacharjee P (1983) The β-adrenergic blockade withdrawal phenomenon. J Cardiovasc Pharmacol 5:S56-S62.
43. 4 receptors by chronic β blocker treatment. Circulation 92:2526-2539.
44. 2 receptor systems in human atrium: Role of cyclic nucleotides. Naunyn-Schmiedeberg's Arch Pharmacol 353:661-670.
45. Sigmund M, Jakob H, Becker H, Hanrath P, Schumacher C, Eschenhagen T, Schmitz W, Scholz H and Steinfath M (1996) Effects of metoprolol on myocardial β-adrenoceptors and Giα-proteins in patients with congestive heart failure. Eur J Clin Pharmacol 51:127-132.
46. Te Velthuis H, Jansen PGM, Oudemans-Van Straaten HM, van Kamp GJ, Sturk A, Eijsman L and Wildevuur RH (1996) Circulating endothelin in cardiac operations: Influence of blood pressure and endotoxin. Ann Thorac Surg 61:904-908.
47. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhäusl and Binder BR (1992) Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 267:16066-16068.